CN102334030A - 利用生物标记监测疗法之方法或系统 - Google Patents

利用生物标记监测疗法之方法或系统 Download PDF

Info

Publication number
CN102334030A
CN102334030A CN201080009568XA CN201080009568A CN102334030A CN 102334030 A CN102334030 A CN 102334030A CN 201080009568X A CN201080009568X A CN 201080009568XA CN 201080009568 A CN201080009568 A CN 201080009568A CN 102334030 A CN102334030 A CN 102334030A
Authority
CN
China
Prior art keywords
cell
methyl
biomarker
monitoring
dim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080009568XA
Other languages
English (en)
Chinese (zh)
Inventor
荒尾德三
工藤可苗
中川和彦
西尾和人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102334030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN102334030A publication Critical patent/CN102334030A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201080009568XA 2009-03-12 2010-03-11 利用生物标记监测疗法之方法或系统 Pending CN102334030A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12
EP09154964.2 2009-03-12
PCT/EP2010/053063 WO2010103058A1 (en) 2009-03-12 2010-03-11 Method or system using biomarkers for the monitoring of a treatment

Publications (1)

Publication Number Publication Date
CN102334030A true CN102334030A (zh) 2012-01-25

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080009568XA Pending CN102334030A (zh) 2009-03-12 2010-03-11 利用生物标记监测疗法之方法或系统

Country Status (24)

Country Link
US (1) US8802384B2 (https=)
EP (1) EP2406628A1 (https=)
JP (1) JP5667581B2 (https=)
KR (1) KR20110137307A (https=)
CN (1) CN102334030A (https=)
AR (1) AR076113A1 (https=)
AU (1) AU2010223256B2 (https=)
BR (1) BRPI1011688A2 (https=)
CA (1) CA2755055A1 (https=)
CL (1) CL2011002260A1 (https=)
CO (1) CO6430497A2 (https=)
EA (1) EA201101300A1 (https=)
EC (1) ECSP11011323A (https=)
IL (1) IL214747A0 (https=)
MA (1) MA33120B1 (https=)
MX (1) MX2011009482A (https=)
NZ (1) NZ594843A (https=)
PE (1) PE20120592A1 (https=)
SG (1) SG174324A1 (https=)
TN (1) TN2011000457A1 (https=)
TW (1) TW201100802A (https=)
UA (1) UA107789C2 (https=)
UY (1) UY32482A (https=)
WO (1) WO2010103058A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104003925A (zh) * 2013-06-05 2014-08-27 四川大学 吲哚酮化合物或其衍生物及其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
MX2010013203A (es) * 2008-06-06 2011-02-25 Boehringer Ingelheim Int Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona.
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671660A (zh) * 2002-07-24 2005-09-21 贝林格尔英格海姆法玛两合公司 3－z－[1－(4－(n－((4－甲基－哌嗪－1－基)－甲羰基)－n－甲基－氨基)－苯氨基)－1－苯基－亚甲基]－6－甲氧羰基－2－吲哚满酮－单乙烷磺酸盐及其作为药物组合物的用途
WO2007141283A2 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Salts and crystalline salt forms of an 2-indolinone derivative
WO2008029123A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
WO2008128008A2 (en) * 2007-04-13 2008-10-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8557531B2 (en) 2006-04-18 2013-10-15 Wellstat Biologics Corporation Detection of circulating endothelial cells
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671660A (zh) * 2002-07-24 2005-09-21 贝林格尔英格海姆法玛两合公司 3－z－[1－(4－(n－((4－甲基－哌嗪－1－基)－甲羰基)－n－甲基－氨基)－苯氨基)－1－苯基－亚甲基]－6－甲氧羰基－2－吲哚满酮－单乙烷磺酸盐及其作为药物组合物的用途
WO2007141283A2 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Salts and crystalline salt forms of an 2-indolinone derivative
WO2008029123A1 (en) * 2006-09-07 2008-03-13 Astrazeneca Ab Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
WO2008128008A2 (en) * 2007-04-13 2008-10-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMMA KULIMOVA等: "Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors", 《MOLECULAR CANCER THERAPEUTICS》 *
FRANCESCO BERTOLINI: "The multifaceted circulating endothelial cell in cancer: towardsmarker and target identification", 《NATURE REVIEWS》 *
FRANK HILBERG等: "BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy", 《CANCER RESEARCH》 *
LAURA VROLING等: "Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib", 《ANGIOGENESIS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104003925A (zh) * 2013-06-05 2014-08-27 四川大学 吲哚酮化合物或其衍生物及其用途
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途

Also Published As

Publication number Publication date
US20100233705A1 (en) 2010-09-16
JP5667581B2 (ja) 2015-02-12
EP2406628A1 (en) 2012-01-18
AU2010223256A1 (en) 2011-09-15
CA2755055A1 (en) 2010-09-16
CO6430497A2 (es) 2012-04-30
IL214747A0 (en) 2011-11-30
ECSP11011323A (es) 2011-10-31
EA201101300A1 (ru) 2012-04-30
AR076113A1 (es) 2011-05-18
PE20120592A1 (es) 2012-06-09
UY32482A (es) 2010-10-29
SG174324A1 (en) 2011-10-28
NZ594843A (en) 2014-03-28
TN2011000457A1 (en) 2013-03-27
MA33120B1 (fr) 2012-03-01
AU2010223256B2 (en) 2014-08-21
UA107789C2 (en) 2015-02-25
US8802384B2 (en) 2014-08-12
WO2010103058A1 (en) 2010-09-16
TW201100802A (en) 2011-01-01
KR20110137307A (ko) 2011-12-22
CL2011002260A1 (es) 2012-03-23
MX2011009482A (es) 2011-09-27
JP2012520446A (ja) 2012-09-06
BRPI1011688A2 (pt) 2016-03-22

Similar Documents

Publication Publication Date Title
Shiozawa et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche
Di Maggio et al. Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma
Lefley et al. Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts
Ellis et al. VEGF-targeted therapy: mechanisms of anti-tumour activity
Shiozawa et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer
CN102334030A (zh) 利用生物标记监测疗法之方法或系统
Dobersalske et al. Cranioencephalic functional lymphoid units in glioblastoma
Shiozawa et al. GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche
Stevenson et al. Bevacizumab and breast cancer: what does the future hold?
CN109072276A (zh) 抗癌剂的评价方法
Ran et al. Lymphatic endothelial cell progenitors in the tumor microenvironment
Coniglio et al. Coculture assays to study macrophage and microglia stimulation of glioblastoma invasion
Belluomini et al. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
CN111971557A (zh) 嗜中性粒细胞亚型
Pu et al. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
Radu-Cosnita et al. Anti-chloride intracellular channel protein 1 (CLIC1) antibodies induce tumour necrosis and angiogenesis inhibition on in vivo experimental models of human renal cancer
Jarrosson et al. An avian embryo patient-derived xenograft model for preclinical studies of human breast cancers
Ceaușu et al. Liver metastatic colorectal tumor cells change their phenotype during consecutive passages on chick embryo chorioallantoic membrane: Lessons from the Lab to the clinic
Dorfmüller et al. Crystalline ultrastructures, inflammatory elements, and neoangiogenesis are present in inconspicuous aortic valve tissue
Lu et al. A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector
Navone et al. Modeling cancer metastasis
HK1162668A (en) Method or system using biomarkers for the monitoring of a treatment
Elledge et al. Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer.
Weissferdt Mesenchymal Tumors of the Mediastinum
Granados Unger Development of a 3D spheroid co-culture model of non-small cell lung cancer cells and fibroblasts for the discovery of novel anti-cancer pharmaceutical agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1162668

Country of ref document: HK

C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120125

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1162668

Country of ref document: HK